← All trials
NCT05470764
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 30, 2021
- Primary completion
- Jun 28, 2021
- Completion date
- Jun 28, 2021
- First posted
- Jul 22, 2022
- Last posted
- Jul 22, 2022
- Enrollment
- 52
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Darnitsa Pharmaceutical CompanyLead sponsor
- International Partnership for MicrobicidesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.